Instil Bio Poised for Growth Amid Biopharmaceutical Sector Activity and Strong Financial Position
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Instil Bio (TIL – Research Report) today and set a price target of ...
Instil Bio price target lowered to $110 from $120 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Instil Bio (TIL) to $110 from $120 and keeps a Buy rating on the shares post the Q3 ...
Vaccines makers close lower on reports RFK Jr may head HHS
Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...
MM&M11h
Merck strikes $3.3B licensing deal for Chinese cancer drug
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
pharmaphorum17h
MSD joins PD-1/VEGF push in cancer with LaNova deal
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
BioNTech signs agreement to acquire Biotheus to enhance tumor treatment capabilities
BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...
Mena FN1d
BioNTech purchases Chinese biotechnology company to improve oncology strategy
(MENAFN) BioNTech signed an agreement to buy Biotheus, which is a Chinese biotechnology firm, for USD800 million to further enhance its treatment of tumors, stated the German medicinal producer ...